

From: [Angulo, Rafael](#)
To: [AGO - High Cost Prescription Drugs](#)
Subject: Notice of Introduction of New High-Cost Prescription Drugs - Attorney General's Office state of Vermont
Date: Friday, March 29, 2019 1:48:46 PM

Attorney General's Office state of Vermont:

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July 1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2) (b) of the § 4637. Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) within 3 calendar days following the release of MAYZENT™ to the commercial market,. See table below:

NDC	DRUG PRODUCT DESCRIPTION	INTRODUCED TO MARKET DATE	WAC AT INTRODUCTION
0078-0986-15	MAYZENT™ is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (SPMS), in adults. MAYZENT™ is available as 2 mg tablet (equivalent to 2.224mg siponimod fumaric acid): pale yellow, unscored, round biconvex film-coated tablet with beveled edges, debossed with on one side and "T" on other side.	3/27/2019	\$7,273.97
0078-0979-50	MAYZENT™ is available as 0.25 mg tablet (equivalent to 0.278mg siponimod fumaric acid): Pale red, unscored, round biconvex film-coated tablet with beveled edges, debossed with on one side and "T" on other side.	3/27/2019	\$1,697.26
0078-0979-12	MAYZENT™ is available as 0.25 mg tablet (equivalent to 0.278mg siponimod fumaric acid): Pale red, unscored, round biconvex film-coated	3/27/2019	N/A

tablet with beveled edges, debossed with on one side and "T" on other side. [STARTER PACK NOT FOR SALE]		
--	--	--

Novartis appreciates the opportunity to respond to this request. Please feel free to contact me with any questions at (862) 778-1818.

Rafael Angulo

Director Government Pricing

Rafael.angulo@novartis.com

T +1 862 778-1818

M +1 862 246 5995

One Health Plaza

Building 135, Office 4442D

East Hanover, NJ 07936-1080